Biotech, Food & Drug

HB Ad Slot
HB Mobile Ad Slot

In today’s hyper-aware environment, concerns about food and drug safety are paramount for both companies and consumers.  The Food and Drug Administration (FDA) and the US Department of Agriculture (USDA) regulates the areas of biotech, food, and drug law. Additionally, laws including the 21st Century Cures Act, and cGMP (Current Good Manufacturing Processes), regulate industry standards/norms in food, cosmetics, and other industry-sectors. Visitors to the National Law Review will find the latest analysis of news, legislation, and upcoming cases/litigation as it relates to this area of law.

With researchers searching for new energy solutions and other developments in biotech, visitors to the NLR will have the opportunity to read content surrounding biosimilars, natural fuel production, medical devices, biotechnology, nanotechnology and materials, and the pharmaceuticals industry. Additionally, content relating to food and drug laws, limits on chemical use in cosmetic products, and other general health/safety topics are covered by the National Law Review and are updated regularly. Additionally, food safety and imports to the United States are also discussed as they become relevant. 

In addition to general health, science, and food/drug, the industry is also closely related to many of the issues related to intellectual property law. New applications for patents, intellectual property, licensing laws, and other areas which are governed by the PTAB court, often crossover into the industry.

New developments in legislation, including the legalization of recreational marijuana has created a new area ripe for legal analysis.  Regulations on how recreational marijuana can be advertised and marketed, distributed and the kind of insurance coverage necessary for dispensaries.  Additionally, employer drug-testing and marijuana statutes have been a hot area of litigation covered by the National Law Review.  

General practices in marketing standards, compliance of federal and state laws/legislation, licensing collaborations, and news related to bringing new products to the market, in the US and abroad, are among the areas visitors to NLR will read about daily. Drug pricing, changes in production standards, regulatory compliance, food safety and handling, drug laws (legalization of marijuana, both recreational and medicinal in the workplace), and labeling and nutritional requirements, are among the many topics covered by the National Law Review daily.

Visitors will always find the latest, up-to-date, most comprehensive coverage on the site. And, news and stories which affect the US, companies which are regulated in the industry, and multinational/international companies, are detailed regularly for NLR readers.

National Law Review Cannabis TwitterFor hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis X (formerly Twitter) feed, and sign up for complimentary e-news bulletins.

Recent Biotechnology, Food & Drug Administration FDA News

Title
Publication Date Organization Sort descending
Dec
10
2021
NYC Council Passes Bill Granting Paid Sick Leave to Parents Vaccinating Children Against COVID-19 Sheppard, Mullin, Richter & Hampton LLP
Dec
21
2021
White May Not Be the Trend in 2022: EU Bans Whitening Food additive E171 as of January 1, 2022 Sheppard, Mullin, Richter & Hampton LLP
Dec
16
2014
Sandoz and Celltrion Decline the Invitation to Dance: Biosimilars Challenge the Applicability of the BPCIA’s Exchange Provisions Before Bringing Suit Sheppard, Mullin, Richter & Hampton LLP
Feb
19
2015
Go For De Novo: FDA’s Revised Approach to Medical Device Accessories Sheppard, Mullin, Richter & Hampton LLP
May
31
2022
Digital Health in the Metaverse: Three Legal Considerations Sheppard, Mullin, Richter & Hampton LLP
Sep
30
2019
New Set Of Guidance From FDA Provides Clarity On Digital Health Policies, Machine Learning Sheppard, Mullin, Richter & Hampton LLP
Dec
13
2022
California’s Newly Adopted “Safe Harbor” Warning Label for Acrylamide In Foods Turns Up the Heat In Ongoing First Amendment Challenge to Proposition 65 Sheppard, Mullin, Richter & Hampton LLP
Jan
20
2023
FDA Approval Mifepristone REMS Program Modification Expands Patient Access to Abortion Care Sheppard, Mullin, Richter & Hampton LLP
Mar
5
2020
How FDA is Reacting to the Coronavirus, and 2020 Regulatory Priorities Sheppard, Mullin, Richter & Hampton LLP
Mar
11
2020
FDA Commissioner Signals Enforcement Policy, Advancement of Research for CBD Products Sheppard, Mullin, Richter & Hampton LLP
Mar
15
2023
CMS Releases First Set of Part B Rebatable Drugs for Coinsurance Adjustment Under IRA Sheppard, Mullin, Richter & Hampton LLP
May
11
2020
The Expansion of Cardiovascular Procedures in the ASC Setting Sheppard, Mullin, Richter & Hampton LLP
Jun
15
2023
Access to Abortion Pill on the Precipice: A Deep Dive into the Federal Court Rulings that will Decide the Fate of Mifepristone Sheppard, Mullin, Richter & Hampton LLP
Jul
13
2020
FDA Announces Plans to Resume Domestic On-site Inspections Sheppard, Mullin, Richter & Hampton LLP
Nov
13
2023
CMS Promotes Competition, Transparency, Health Equity and More in the CY2025 Medicare Advantage and Part D Proposed Rule Sheppard, Mullin, Richter & Hampton LLP
Jun
23
2013
Federal Trade Commission (FTC) v. Actavis: What Does It Mean for Reverse-Payment Settlements? Sheppard, Mullin, Richter & Hampton LLP
Jul
4
2013
European Union (EU) Carbon Trading System Wins Parliament's Support Sheppard, Mullin, Richter & Hampton LLP
Jun
26
2018
Ninth Circuit Confirms that Class Action Plaintiffs Must Plausibly Establish Future Intent To Re-Purchase To Maintain Claims for Injunctive Relief Sheppard, Mullin, Richter & Hampton LLP
Apr
29
2021
“Buy American” Update: Essential Medicines May Continue to Come From Abroad (For Now) Sheppard, Mullin, Richter & Hampton LLP
May
8
2019
AAFCO Issues Updated Guidelines Regarding Hemp in Animal Food Sheppard, Mullin, Richter & Hampton LLP
Jan
12
2022
FDA Releases Guidances on Transition Plan for Devices Distributed Under Emergency Use Authorization (EUA) or Enforcement Policies During COVID-19 Sheppard, Mullin, Richter & Hampton LLP
May
20
2019
Location Matters – Manufacturing Insights from FDA’s Annual Report on Drug Quality Sheppard, Mullin, Richter & Hampton LLP
Sep
30
2019
CBD Industry Beware: The False Labeling Class Action Has Arrived Sheppard, Mullin, Richter & Hampton LLP
Oct
3
2019
Third Circuit Holds that SLUSA Does Not Preclude Class Action Opt-Outs from Pursuing Individual Actions Sheppard, Mullin, Richter & Hampton LLP
Oct
30
2019
BREAKING NEWS: USDA Releases Interim Final Hemp Rule Sheppard, Mullin, Richter & Hampton LLP
Jan
10
2016
Fourth Circuit Holds Consequential Damages Exclusion Bars $19 Million Fire Loss Claim Poyner Spruill LLP
Feb
13
2014
Proposed Fracking Setback Rules Approved in North Carolina Poyner Spruill LLP
Dec
21
2015
Does My Company Really Need to Have Written Policy on Drug and Alcohol Testing? Poyner Spruill LLP
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins